WO1996022773A1 - Methods and compositions for lipidization of hydrophilic molecules - Google Patents
Methods and compositions for lipidization of hydrophilic molecules Download PDFInfo
- Publication number
- WO1996022773A1 WO1996022773A1 PCT/US1996/001052 US9601052W WO9622773A1 WO 1996022773 A1 WO1996022773 A1 WO 1996022773A1 US 9601052 W US9601052 W US 9601052W WO 9622773 A1 WO9622773 A1 WO 9622773A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipid
- group
- compound
- hydrogen
- bbi
- Prior art date
Links
- RSHXRTLOTSYSRD-UXMRNZNESA-N CCCCCCCCCCCCCCCC(N[C@@H](CSSC1CCCC1)C(C)(O)O)O Chemical compound CCCCCCCCCCCCCCCC(N[C@@H](CSSC1CCCC1)C(C)(O)O)O RSHXRTLOTSYSRD-UXMRNZNESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA199700143A EA000584B1 (en) | 1995-01-25 | 1996-01-25 | Conjugates of a compound containing sulfhydryl group and fatty acid derivatives, method of obtaining conjugates, intermediate compounds for obtaining thereof, methods of increasing absorption and prolonged blood and tissue retention of the compound by mammalian cells containing sulfhydryl group |
JP52301596A JP3814294B2 (en) | 1995-01-25 | 1996-01-25 | Methods and compositions for lipidation of hydrophilic molecules |
AT96903690T ATE240729T1 (en) | 1995-01-25 | 1996-01-25 | METHODS AND COMPOSITIONS FOR LIPIDIZING HYDROPHILIC MOLECULES |
DE69628290T DE69628290T2 (en) | 1995-01-25 | 1996-01-25 | METHODS AND COMPOSITIONS FOR LIPIDIZING HYDROPHILIC MOLECULES |
AU47692/96A AU699827B2 (en) | 1995-01-25 | 1996-01-25 | Methods and compositions for lipidization of hydrophilic molecules |
EP96903690A EP0820285B1 (en) | 1995-01-25 | 1996-01-25 | Methods and compositions for lipidization of hydrophilic molecules |
FI973048A FI973048A (en) | 1995-01-25 | 1997-07-18 | Methods and compositions for lipidizing hydrophilic molecules |
NO973403A NO973403L (en) | 1995-01-25 | 1997-07-23 | Method and Preparation for Lipidization of Hydrophilic Molecules |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34971795A | 1995-01-25 | 1995-01-25 | |
US08/349,717 | 1995-01-25 | ||
US08/524,362 | 1995-09-05 | ||
US08/524,362 US5907030A (en) | 1995-01-25 | 1995-09-05 | Method and compositions for lipidization of hydrophilic molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996022773A1 true WO1996022773A1 (en) | 1996-08-01 |
Family
ID=26996314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/001052 WO1996022773A1 (en) | 1995-01-25 | 1996-01-25 | Methods and compositions for lipidization of hydrophilic molecules |
Country Status (14)
Country | Link |
---|---|
US (4) | US5907030A (en) |
EP (2) | EP1327628B1 (en) |
JP (1) | JP3814294B2 (en) |
KR (1) | KR100438268B1 (en) |
CN (1) | CN1139385C (en) |
AT (2) | ATE371643T1 (en) |
AU (1) | AU699827B2 (en) |
CA (1) | CA2211442A1 (en) |
DE (2) | DE69628290T2 (en) |
EA (1) | EA000584B1 (en) |
ES (1) | ES2200051T3 (en) |
FI (1) | FI973048A (en) |
NO (1) | NO973403L (en) |
WO (1) | WO1996022773A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6093692A (en) * | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
EP1023316A2 (en) * | 1996-09-26 | 2000-08-02 | University Of Southern California | Methods and compositions for lipidization of hydrophilic molecules |
WO2000067800A2 (en) * | 1999-05-07 | 2000-11-16 | Pharmasol Gmbh | Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates |
JP2002531543A (en) * | 1998-12-10 | 2002-09-24 | ユニバーシティ・オブ・サザン・カリフォルニア | Reversible aqueous pH-sensitive lipidating agents, compositions and methods of use |
US7052704B2 (en) | 1995-01-25 | 2006-05-30 | University Of Southern California | Methods and compositions for lipidization of hydrophilic molecules |
EP1663933A2 (en) * | 2003-09-08 | 2006-06-07 | Mirus Bio Corporation | Improved delivery by labile hydrophobic modification of drugs |
US8486384B2 (en) | 2006-10-27 | 2013-07-16 | University Of Southern California | Lipidized interferon and methods of treating viral hepatitis |
WO2022157548A1 (en) | 2021-01-24 | 2022-07-28 | Forrest Michael David | Inhibitors of atp synthase - cosmetic and therapeutic uses |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
GB9704519D0 (en) * | 1997-03-05 | 1997-04-23 | Smithkline Beecham Plc | Compounds |
WO2000069898A2 (en) | 1999-05-14 | 2000-11-23 | Arbor Vita Corporation | Molecular interactions in allergy cells |
US6309633B1 (en) * | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
US20030054015A1 (en) * | 2000-12-25 | 2003-03-20 | Shinichiro Haze | Sympathetic-activating perfume composition |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7125568B2 (en) | 2001-08-23 | 2006-10-24 | Sung Michael T | Lipophilic drug compositions |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7166571B2 (en) * | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7196059B2 (en) * | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US6913903B2 (en) * | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
BR0212985A (en) | 2001-09-24 | 2005-08-30 | Imp College Innovations Ltd | Use of pyy or an agonist in the preparation of medicaments for treating disorders associated with overweight |
GB0129121D0 (en) * | 2001-12-05 | 2002-01-23 | Ic Vec Ltd | Compound |
JP4733922B2 (en) | 2002-01-10 | 2011-07-27 | インペリアル・イノベ−ションズ・リミテッド | Correction of eating behavior |
US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
US7285289B2 (en) * | 2002-04-12 | 2007-10-23 | Nagy Jon O | Nanoparticle vaccines |
US20080233181A1 (en) * | 2002-04-12 | 2008-09-25 | Nagy Jon O | Nanoparticle adjuvants for sub-unit vaccines |
GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
US20040151766A1 (en) * | 2003-01-30 | 2004-08-05 | Monahan Sean D. | Protein and peptide delivery to mammalian cells in vitro |
US20090074885A1 (en) * | 2003-09-08 | 2009-03-19 | Roche Madison Inc. | Reversible Hydrophobic Modification of Drugs for Improved Delivery to Cells |
US20080119412A1 (en) | 2003-12-23 | 2008-05-22 | Nono Inc. | Polypeptides for Modulating Binding of Trp Channel Proteins and Trp- Associated Proteins |
US7282590B2 (en) * | 2004-02-12 | 2007-10-16 | The Research Foundation Of State University Of New York | Drug conjugates |
EP1773878B1 (en) | 2004-07-19 | 2015-03-04 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
EP1695717A1 (en) * | 2005-02-23 | 2006-08-30 | Ludwig-Maximilians-Universität | Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells |
GB0504857D0 (en) * | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
ATE553124T1 (en) | 2005-06-13 | 2012-04-15 | Imp Innovations Ltd | OXYNTOMODULIN ANALOGS AND THEIR EFFECTS ON EATING BEHAVIOR |
GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
JP4879988B2 (en) | 2005-09-29 | 2012-02-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
US20070232537A1 (en) * | 2005-12-19 | 2007-10-04 | Nastech Pharmaceutical Company Inc. | Intranasal pyy formulations with improved transmucosal pharmacokinetics |
CA2770486C (en) | 2006-09-22 | 2014-07-15 | Merck Sharp & Dohme Corp. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
TWI428346B (en) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
CA2693392A1 (en) | 2007-07-09 | 2009-01-15 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
WO2009050738A2 (en) * | 2007-10-16 | 2009-04-23 | Biocon Limited | An orally administerable solid pharmaceutical composition and a process thereof |
WO2009059984A2 (en) * | 2007-11-06 | 2009-05-14 | F. Hoffmann-La Roche Ag | Reversible hydrophobization of antitumor drugs for enhanced first-pass drug uptake |
GB0918579D0 (en) | 2009-10-22 | 2009-12-09 | Imp Innovations Ltd | Gadd45beta targeting agents |
GB201001333D0 (en) | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
GB201107118D0 (en) | 2011-04-27 | 2011-06-08 | Imp Innovations Ltd | Method of diagnosis and prognosis |
US9944687B2 (en) | 2011-07-04 | 2018-04-17 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
US20170137486A1 (en) | 2014-05-23 | 2017-05-18 | Imperial Innovations Limited | Peptide yy (pyy) analogues |
GB201720187D0 (en) | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Novel Compounds |
GB201720188D0 (en) | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Analogues of PYY |
GB201908424D0 (en) | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Novel compounds |
JP2024501467A (en) | 2020-12-11 | 2024-01-12 | アイピー2アイピーオー イノベ-ションズ リミテッド | new compound |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63246382A (en) * | 1987-04-02 | 1988-10-13 | Karupisu Shokuhin Kogyo Kk | Biotinyl reagent and biotinylation using said reagent |
US5599903A (en) * | 1992-04-03 | 1997-02-04 | Terrapin Technologies, Inc. | Glutathione analogs and paralog panels comprising glutathione mimics |
US5679643A (en) * | 1987-10-13 | 1997-10-21 | Terrapin Technologies, Inc. | Glutathione analogs and paralog panels comprising glutathione mimics |
US5157123A (en) * | 1989-03-13 | 1992-10-20 | Georgetown University | S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent |
IE911351A1 (en) * | 1990-04-23 | 1991-10-23 | Res Corp Technologies Inc | Soluble tyrosine and cysteine source for total parenteral¹nutrition |
US5629020A (en) * | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
JP3091270B2 (en) * | 1990-09-28 | 2000-09-25 | 協和醗酵工業株式会社 | Whitening cosmetics |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5635380A (en) * | 1994-01-18 | 1997-06-03 | Vanderbilt University | Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids |
US5907030A (en) | 1995-01-25 | 1999-05-25 | University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
CA2260761C (en) | 1996-06-25 | 2011-05-03 | Nico Johannes Christiaan Maria Beekman | Vaccine comprising antigens bound to carriers through labile bonds |
-
1995
- 1995-09-05 US US08/524,362 patent/US5907030A/en not_active Expired - Fee Related
-
1996
- 1996-01-25 DE DE69628290T patent/DE69628290T2/en not_active Expired - Fee Related
- 1996-01-25 EP EP03006780A patent/EP1327628B1/en not_active Expired - Lifetime
- 1996-01-25 ES ES96903690T patent/ES2200051T3/en not_active Expired - Lifetime
- 1996-01-25 EA EA199700143A patent/EA000584B1/en not_active IP Right Cessation
- 1996-01-25 WO PCT/US1996/001052 patent/WO1996022773A1/en active IP Right Grant
- 1996-01-25 DE DE69637229T patent/DE69637229T2/en not_active Expired - Lifetime
- 1996-01-25 AT AT03006780T patent/ATE371643T1/en not_active IP Right Cessation
- 1996-01-25 JP JP52301596A patent/JP3814294B2/en not_active Expired - Fee Related
- 1996-01-25 AU AU47692/96A patent/AU699827B2/en not_active Ceased
- 1996-01-25 CN CNB961921285A patent/CN1139385C/en not_active Expired - Fee Related
- 1996-01-25 CA CA002211442A patent/CA2211442A1/en not_active Abandoned
- 1996-01-25 EP EP96903690A patent/EP0820285B1/en not_active Expired - Lifetime
- 1996-01-25 AT AT96903690T patent/ATE240729T1/en not_active IP Right Cessation
- 1996-01-25 KR KR1019970705063A patent/KR100438268B1/en not_active IP Right Cessation
- 1996-11-01 US US08/742,357 patent/US5936092A/en not_active Expired - Fee Related
-
1997
- 1997-07-18 FI FI973048A patent/FI973048A/en unknown
- 1997-07-23 NO NO973403A patent/NO973403L/en not_active Application Discontinuation
-
1998
- 1998-07-22 US US09/120,118 patent/US6225445B1/en not_active Expired - Fee Related
-
2001
- 2001-05-01 US US09/845,153 patent/US7052704B2/en not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 121, No. 21, 21 November 1994, (Columbus, Ohio, USA), CHU et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide", page 212, Abstract No. 246582y; & BIOCHEMISTRY, 1994, 33(4), 13087-92(Eng). * |
CHEMICAL ABSTRACTS, Volume 124, No. 3, 15 January 1996, (Columbus, Ohio, USA), EKRAMI H.M. et al., "Water-Soluble Fatty Acid Derivatives as Acylating Agents for Reversible Lipidization of Polypeptides", page 1042, Abstract No. 30361q; & FEBS LETTERS, 1995, 371(3), 283-6(Eng). * |
MOLECULAR IMMUNOLOGY, October 1994, Vol. 31, No. 15, HUANG et al., "Lipophilic Multiple Antigen Peptide System for Peptide Immunogen and Synthetic Vaccine", pages 1191-1199. * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7052704B2 (en) | 1995-01-25 | 2006-05-30 | University Of Southern California | Methods and compositions for lipidization of hydrophilic molecules |
EP1023316A2 (en) * | 1996-09-26 | 2000-08-02 | University Of Southern California | Methods and compositions for lipidization of hydrophilic molecules |
KR100691315B1 (en) * | 1996-09-26 | 2007-03-12 | 유니버시티 오브 써던 캘리포니아 | Methods and compositions for lipidization of hydrophilic molecules |
EP1023316A4 (en) * | 1996-09-26 | 2004-06-09 | Univ Southern California | Methods and compositions for lipidization of hydrophilic molecules |
US6093692A (en) * | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
JP2002531543A (en) * | 1998-12-10 | 2002-09-24 | ユニバーシティ・オブ・サザン・カリフォルニア | Reversible aqueous pH-sensitive lipidating agents, compositions and methods of use |
US6590071B1 (en) | 1998-12-10 | 2003-07-08 | University Of Southern California | Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use |
WO2000067800A3 (en) * | 1999-05-07 | 2001-05-10 | Pharmasol Gmbh | Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates |
US6770299B1 (en) * | 1999-05-07 | 2004-08-03 | Pharmasol Gmbh | Lipid matrix-drug conjugates particle for controlled release of active ingredient |
WO2000067800A2 (en) * | 1999-05-07 | 2000-11-16 | Pharmasol Gmbh | Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates |
EP1663933A2 (en) * | 2003-09-08 | 2006-06-07 | Mirus Bio Corporation | Improved delivery by labile hydrophobic modification of drugs |
EP1663933A4 (en) * | 2003-09-08 | 2010-10-27 | Mirus Bio Corp | Improved delivery by labile hydrophobic modification of drugs |
US8486384B2 (en) | 2006-10-27 | 2013-07-16 | University Of Southern California | Lipidized interferon and methods of treating viral hepatitis |
WO2022157548A1 (en) | 2021-01-24 | 2022-07-28 | Forrest Michael David | Inhibitors of atp synthase - cosmetic and therapeutic uses |
Also Published As
Publication number | Publication date |
---|---|
DE69628290T2 (en) | 2004-03-18 |
NO973403L (en) | 1997-09-17 |
US20040054132A1 (en) | 2004-03-18 |
US6225445B1 (en) | 2001-05-01 |
EP0820285A4 (en) | 1998-04-22 |
KR19980701667A (en) | 1998-06-25 |
EP0820285B1 (en) | 2003-05-21 |
JPH11500108A (en) | 1999-01-06 |
FI973048A0 (en) | 1997-07-18 |
CN1139385C (en) | 2004-02-25 |
US7052704B2 (en) | 2006-05-30 |
NO973403D0 (en) | 1997-07-23 |
EP1327628A3 (en) | 2003-08-13 |
EA199700143A1 (en) | 1997-12-30 |
FI973048A (en) | 1997-09-16 |
JP3814294B2 (en) | 2006-08-23 |
US5907030A (en) | 1999-05-25 |
DE69628290D1 (en) | 2003-06-26 |
DE69637229D1 (en) | 2007-10-11 |
AU4769296A (en) | 1996-08-14 |
US5936092A (en) | 1999-08-10 |
EP0820285A1 (en) | 1998-01-28 |
ATE371643T1 (en) | 2007-09-15 |
ATE240729T1 (en) | 2003-06-15 |
EP1327628B1 (en) | 2007-08-29 |
CN1175902A (en) | 1998-03-11 |
EP1327628A2 (en) | 2003-07-16 |
CA2211442A1 (en) | 1996-08-01 |
ES2200051T3 (en) | 2004-03-01 |
AU699827B2 (en) | 1998-12-17 |
EA000584B1 (en) | 1999-12-29 |
DE69637229T2 (en) | 2008-05-15 |
KR100438268B1 (en) | 2004-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5907030A (en) | Method and compositions for lipidization of hydrophilic molecules | |
US6093692A (en) | Method and compositions for lipidization of hydrophilic molecules | |
JP4358521B2 (en) | Conjugates and compositions for cellular delivery | |
US7553830B2 (en) | Compositions for the delivery of negatively charged molecules | |
US7833992B2 (en) | Conjugates and compositions for cellular delivery | |
US20030130186A1 (en) | Conjugates and compositions for cellular delivery | |
US20040249178A1 (en) | Conjugates and compositions for cellular delivery | |
CA2238379A1 (en) | Ligands to enhance cellular uptake of biomolecules | |
KR102015524B1 (en) | [GRO Aptamer]-Drug Conjugates And Use Thereof | |
AU737865B2 (en) | Methods and compositions for lipidization of hydrophilic molecules | |
WO1998013007A9 (en) | Methods and compositions for lipidization of hydrophilic molecules | |
CN114716518A (en) | Molecular structure capable of inhibiting expression of PCSK9 and pharmaceutical composition | |
US20220054645A1 (en) | Targeted Delivery of Therapeutic Molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96192128.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AZ BY KG KZ RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 973048 Country of ref document: FI |
|
ENP | Entry into the national phase |
Ref document number: 2211442 Country of ref document: CA Ref document number: 2211442 Country of ref document: CA Kind code of ref document: A Ref document number: 1996 523015 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970705063 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996903690 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 199700143 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1996903690 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970705063 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996903690 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970705063 Country of ref document: KR |